GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » PS Ratio

LUCD (Lucid Diagnostics) PS Ratio : 17.65 (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lucid Diagnostics's share price is $1.50. Lucid Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.09. Hence, Lucid Diagnostics's PS Ratio for today is 17.65.

Warning Sign:

Lucid Diagnostics Inc stock PS Ratio (=16.92) is close to 1-year high of 18.59.

The historical rank and industry rank for Lucid Diagnostics's PS Ratio or its related term are showing as below:

LUCD' s PS Ratio Range Over the Past 10 Years
Min: 8.68   Med: 77   Max: 2178
Current: 17.66

During the past 6 years, Lucid Diagnostics's highest PS Ratio was 2178.00. The lowest was 8.68. And the median was 77.00.

LUCD's PS Ratio is ranked worse than
91.93% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 3.02 vs LUCD: 17.66

Lucid Diagnostics's Revenue per Sharefor the three months ended in Dec. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.09.

During the past 12 months, the average Revenue per Share Growth Rate of Lucid Diagnostics was 48.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 47.10% per year.

During the past 6 years, Lucid Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 47.10% per year. The lowest was 47.10% per year. And the median was 47.10% per year.

Back to Basics: PS Ratio


Lucid Diagnostics PS Ratio Historical Data

The historical data trend for Lucid Diagnostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics PS Ratio Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
Get a 7-Day Free Trial - 198.89 136.00 24.31 9.52

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.31 11.57 9.53 9.06 9.52

Competitive Comparison of Lucid Diagnostics's PS Ratio

For the Medical Devices subindustry, Lucid Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's PS Ratio falls into.


;
;

Lucid Diagnostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Lucid Diagnostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.50/0.085
=17.65

Lucid Diagnostics's Share Price of today is $1.50.
Lucid Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Lucid Diagnostics  (NAS:LUCD) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Lucid Diagnostics PS Ratio Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165